|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's Range||84.76 - 87.61|
|52 Week Range||69.36 - 94.75|
|Beta (5Y Monthly)||0.97|
|PE Ratio (TTM)||21.00|
|Earnings Date||Jan 29, 2020 - Feb 3, 2020|
|Forward Dividend & Yield||1.60 (1.84%)|
|1y Target Est||93.69|
Teva shares are climbing after the pharmaceutical company raised its guidance for the year. Yahoo Finance’s Akiko Fujita and Ines Ferre break down the quarterly earnings results on The Ticker.
AmerisourceBergen (ABC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Low-cost index funds make it easy to achieve average market returns. But if you invest in individual stocks, some are...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
The stock prices of opioid drugmakers and distributors fell this week after news of a possible federal criminal probe, eroding many of the gains made in the weeks since a global settlement resolving opioid litigation was first announced.
Shares of companies caught up in the opioid litigation have risen recently, but a Wall Street Journal report appears to have reminded investors that the trouble could continue.
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Pharmaceutical companies are in trouble over their role in fueling the opioid crisis facing the U.S. What Happened Federal authorities have launched a criminal investigation against the companies — using ...
Shares of pharmaceuticals companies Teva, Amneal and Mallinckrodt slumped Tuesday on a report that federal prosecutors have opened a criminal investigation into the opioid epidemic.
Shares of the companies embroiled in opioid litigation fell in afternoon trading afterThe Wall Street Journal reported the federal government had opened a criminal investigation into some opioid makers and distributors, citing sources. Six companies have disclosed in regulatory filings that they have received grand-jury subpoenas from the U.S. attorney's office in the Eastern District of New York, according to the report. Teva Pharmaceutical Industries Ltd. is down 8%, Mallinckrodt 5%, Amneal Pharmaceuticals Inc. 10%, and Johnson & Johnson 1%. Shares of cited wholesale drug distributors also declined, AmerisourceBergen by 3% and McKesson by 5%. In addition, shares of companies facing opioid litigation but not cited in the Journal story also dropped, with Endo International down 9% and Cardinal Health 4%. In recent weeks, the stocks of these companies have rallied as investors took the view that the possibility of global settlement that would resolve all pending and future litigation was a positive.
AmerisourceBergen Corp. plans an expansion to its pharmaceutical distribution facility near Rickenbacker International Airport that would make it the largest in the company.
AmerisourceBergen Corporation (NYSE:ABC) received a lot of attention from a substantial price movement on the NYSE...
As shares of (TEVA) soared 10% after the company reported solid earnings on Thursday, CEO Kåre Schultz said the litigation the company faces over its alleged role in the opioid crisis could be resolved by the end of this year. “I think that’s a realistic timeline,” Schultz said in an interview with Barron’s. If that happens, it would lift a weight that has helped drive Teva (ticker: TEVA) shares down 81% between the end of October in 2016 and the end of October this year.
The sprawling litigation seeking to extract billions from corporations over the opioid crisis is far from over, but investors could be forgiven for thinking it was on Thursday morning.
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 1.90% and 0.68%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
A growing number of skeptics are casting doubt on the financial case for taking Walgreens Boots Alliance private in a debt-financed buyout.
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
AmerisourceBergen (ABC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CVS Health's (CVS) Caremark legacy business is expected to have delivered a solid third quarter, backed by the company's robust execution of its formulary and cost-containment tools.